Industry
Biotechnology
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Loading...
Open
3.81
Mkt cap
300M
Volume
41K
High
3.85
P/E Ratio
-28.38
52-wk high
10.76
Low
3.62
Div yield
N/A
52-wk low
3.62
Portfolio Pulse from
November 28, 2024 | 3:45 pm
Portfolio Pulse from
November 26, 2024 | 5:00 pm
Portfolio Pulse from
November 07, 2024 | 6:15 am
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 3:46 pm
Portfolio Pulse from Avi Kapoor
October 11, 2024 | 1:04 pm
Portfolio Pulse from Benzinga Insights
October 11, 2024 | 12:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 11, 2024 | 10:22 am
Portfolio Pulse from Benzinga Insights
September 25, 2024 | 12:01 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.